Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 363 clinical trials
Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19

Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of COVID-19

ivermectin
SARS
covid-19
acute respiratory syndrome (sars)
  • 0 views
  • 19 Feb, 2024
  • 1 location
Waking Hypnosis in the Treatment of MS-related Fatigue

The proposed study is a single-center, single-blind three-group randomized (1:1:1) controlled trial (RCT) comparing two hypnosis interventions to waitlist control efficacy for MS-related fatigue.

fatigue
  • 0 views
  • 19 Feb, 2024
  • 1 location
Dose Escalation Study of PF-07209326 in Healthy Participants

This Phase 1 first-in-human single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Evaluate the Safety and Efficacy of Botulax in Subjects With Benign Masseteric Hypertrophy

This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax in Subjects with Benign Masseteric Hypertrophy

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

  • 0 views
  • 20 Sep, 2024
  • 11 locations
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease

chest imaging
FIO2
fraction of inspired oxygen (fio2)
pao2
coronavirus infection
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

A mucosal melanoma postoperative adjuvant treatment of multicenter, randomized, double-blind, placebo-controlled phase II study, evaluation of mucosal melanoma patients accept completely resected, Toripalima Combined with Temozolomide and Cisplatin postoperative adjuvant therapy efficacy and safety

metastasis
temozolomide
toripalimab
PET-CT
adjuvant therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID 19)

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

chest ct
oximetry
administered intravenously
FIO2
fraction of inspired oxygen (fio2)
  • 0 views
  • 19 Feb, 2024
  • 1 location
Efficacy and Safety of Polyoxidonium in Hospitalized Patients With Coronavirus Disease COVID-19

The purpose of this study is to demonstrate the superiority of Polyoxidonium, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIb\IIIa clinical trial.

mechanical ventilation
coronavirus infection
acute respiratory syndrome (sars)
SARS
covid-19
  • 0 views
  • 19 Feb, 2024
  • 12 locations
Tolerability Safety Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal antibody)

  • 0 views
  • 19 Feb, 2024
  • 1 location